USP5 and neoplasm: Based on the scRNA-Seq data of NPC, melanoma, and colon cancer, we found that USP5 was dominantly expressed in tumor cells (Figure 1K and Supplemental Figure 2, E and F), indicating that tumor-intrinsic USP5 might inhibit IFN-I response and CXCL9hi macrophage–CD8+ T cell antitumor immunity.